Related Experiment Videos

Markers of bone metabolism in congestive heart failure

Armin Zittermann1, Stefanie S Schleithoff, Reiner Koerfer

  • 1Department of Cardio-Thoracic Surgery, Heart Center Northrhine Westfalia, Ruhr University of Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany. azittermann@hdz-nrw.de

Clinica Chimica Acta; International Journal of Clinical Chemistry
|November 30, 2005
PubMed

Insights

Congestive heart failure (CHF) patients show subtle bone metabolism changes. Heart transplant recipients face higher osteoporosis risk due to immunosuppressants, but prevention can mitigate bone loss.

Area of Science:

  • Cardiology
  • Endocrinology
  • Bone Metabolism

Background:

  • Congestive heart failure (CHF) is a growing concern, particularly in the elderly, leading to symptoms like dyspnea and edema.
  • Risk factors in CHF, including immobility and certain medications, may contribute to osteoporosis.
  • Cardiac transplantation is a vital treatment for end-stage CHF.

Purpose of the Study:

  • To review bone metabolism markers in congestive heart failure (CHF) patients and heart transplant recipients.
  • To explore the impact of CHF and its treatments on bone health.
  • To discuss strategies for preventing bone loss post-heart transplantation.

Main Methods:

  • Literature review focusing on bone metabolism markers.
  • Analysis of physiological aspects of bone metabolism.
  • Summary of bone formation and resorption markers.
  • Examination of data on pre- and post-heart transplant patients.

Main Results:

  • Pre-transplant CHF patients exhibit only minor disturbances in bone metabolism.
  • Heart transplant recipients are at significantly increased risk of osteoporotic bone loss.
  • Immunosuppressive agents like corticosteroids and calcineurin inhibitors are key contributors to bone loss.

Conclusions:

  • Bone metabolism disturbances in CHF patients are generally subtle.
  • Heart transplantation significantly elevates osteoporosis risk due to immunosuppression.
  • Preventive measures are crucial for normalizing bone metabolism and reducing bone loss in the first year post-transplant.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...